<DOC>
	<DOC>NCT00709683</DOC>
	<brief_summary>This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix速 30 FlexPen速 under normal clinical practice conditions.</brief_summary>
	<brief_title>Observational Study to Evaluate the Safety of NovoMix速 30 FlexPen速</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes having failed on basal insulin with or without OAD HbA1c greater than 7.0% Subjects being unlikely to comply with protocol requirements Subjects who previously enrolled in this study Subjects with hypersensitivity to biphasic insulin aspart or any of the excipients Women who are pregnant, breast feeding and women in child bearing capacity who are not using reliable contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>